Biotech Values

[iwfal]

ISIS - FXIRX competitor. Another drug (ichorcumab) with potential to be very good anti coagulant but with minimal excess bleeding risk. And at the macro/mechanical level the same explanation is given: Thrombosis risk is about clot growth, bleeding is about micro clotting (I.e. Capillaries or totality of other small bleeds). FXIRx and ichorcumab both shut down the former while not effecting the latter.

http://www.tcpinnovations.com/drugbaron/ichorcumab-the-blood-of-the-gods/

HT @michael_gilman